Cargando…
Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Becaris Publishing Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288950/ https://www.ncbi.nlm.nih.gov/pubmed/36515082 http://dx.doi.org/10.2217/cer-2022-0106 |
| _version_ | 1785062179863527424 |
|---|---|
| author | Ballew, Nick Mian, Aneela Levy, Roger Abramino Bradley, Matt |
| author_facet | Ballew, Nick Mian, Aneela Levy, Roger Abramino Bradley, Matt |
| author_sort | Ballew, Nick |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10288950 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Becaris Publishing Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102889502023-08-11 Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus Ballew, Nick Mian, Aneela Levy, Roger Abramino Bradley, Matt J Comp Eff Res Letter to the Editor Becaris Publishing Ltd 2022-12-14 /pmc/articles/PMC10288950/ /pubmed/36515082 http://dx.doi.org/10.2217/cer-2022-0106 Text en © 2022 GlaxoSmithKline https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
| spellingShingle | Letter to the Editor Ballew, Nick Mian, Aneela Levy, Roger Abramino Bradley, Matt Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus |
| title | Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus |
| title_full | Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus |
| title_fullStr | Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus |
| title_full_unstemmed | Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus |
| title_short | Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus |
| title_sort | letter to the editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288950/ https://www.ncbi.nlm.nih.gov/pubmed/36515082 http://dx.doi.org/10.2217/cer-2022-0106 |
| work_keys_str_mv | AT ballewnick lettertotheeditorindirecttreatmentcomparisonofanifrolumabefficacyversusbelimumabinadultswithsystemiclupuserythematosus AT miananeela lettertotheeditorindirecttreatmentcomparisonofanifrolumabefficacyversusbelimumabinadultswithsystemiclupuserythematosus AT levyrogerabramino lettertotheeditorindirecttreatmentcomparisonofanifrolumabefficacyversusbelimumabinadultswithsystemiclupuserythematosus AT bradleymatt lettertotheeditorindirecttreatmentcomparisonofanifrolumabefficacyversusbelimumabinadultswithsystemiclupuserythematosus |